TACTIC-E

Multi-Arm Therapeutic Study in Pre-ICU Patients Admitted with COVID-19 – Evaluating new drugs against COVID-19

Research summary

The TACTIC-E clinical trial is testing whether novel therapeutic agents or novel combinations of approved agents can prevent the development of severe symptoms in patients hospitalised with strongly suspected or confirmed COVID-19. By targeting the exaggerated host response mechanism driving the severe lung and other organ damage seen in coronavirus infection, this approach is a way of finding out whether these novel approaches are effective in treating the disease.

The treatments currently being tested in TACTIC-E are:

  • ADP1815 - to modulate abnormal immune and inflammatory response to active viral infection

  • Ambrisentan in combination with Dapagliflozin - to treat respiratory, cardiovascular and renal complications from COVID-19

    The platform design by TACTIC-E provides flexibility to swap out and add in alternative treatments based on emerging data as the trial progresses

Main inclusion criteria

This trial is recruiting people who have been hospitalised with confirmed COVID-19 disease. The purpose of this trial is to prevent organ damage and reduce the need to transfer patients to ICU and ventilation.

Patients may be invited to participate in this trial if they are or are suspected to be COVID-19 positive, are considered to be at higher risk of developing serious symptoms, and where it is believed Ambrisentan and Dapagliflozin or EDP1815 may be suitable treatment.

We plan to include up to 469 patients (in each arm) with COVID-19 disease from a number of hospitals across the UK.

There is no guarantee that you will benefit from taking part in this trial. However, information collected as part of your participation in this trial may benefit patients with COVID-19 in the future.

 

 

Funders and sponsors

Chief investigator

Chief Investigator: Dr Joseph Cheriyan

Co-Lead: Dr James Galloway

Contact details

Senior Clinical Trials Coordinator: Heike Templin
Telephone: 01223 250874 | Email: [email protected]